Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | IFNAR1 | P17181 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17058596 | 0.83 | IFNAR1 (0.43) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL6293960 | 0.83 | IFNAR1 (0.43) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL29364906 | 0.80 | HTR7 (0.47) | ALDH1A1LMNAMAPK1MAPTNPSR1 | |
| SCHEMBL890866 | 0.80 | HTR7 (0.47) | ALDH1A1LMNAMAPK1MAPTNPSR1 | |
| SCHEMBL1493098 | 0.80 | IFNAR1 (0.41) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL29137793 | 0.80 | IFNAR1 (0.41) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL8038665 | 0.80 | IFNAR1 (0.41) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL2607777 | 0.80 | IFNAR1 (0.45) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL2607764 | 0.80 | ALDH1A1 (0.44) | ALDH1A1LMNAMAPK1NPY1RNPY2R | |
| SCHEMBL2607563 | 0.79 | HTR7 (0.59) | ALDH1A1LMNAMAPK1NPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118055922-A | Naphthalene dithiol and its derivatives, and their preparation method and use | 菅井化学工业株式会社 | 2024-05-17 | — | — | CN | disclosed |
| US-9889115-B2 | Fitness assay and associated methods | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-02-13 | — | — | US | disclosed |
| EP-1088098-B2 | FITNESS ASSAY AND METHODS FOR REDUCING RESISTANCE OF HIV TO THERAPY | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2015-07-01 | — | — | EP | disclosed |
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-01-09 | — | — | US | disclosed |
| US-8597876-B2 | Method of treating HIV infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2013-12-03 | — | — | US | disclosed |
| US-8003627-B2 | Urokinase inhibitors | UNIVERSITEIT ANTWERPEN (BE) | 2011-08-23 | — | — | US | disclosed |
| US-7981875-B2 | Treating pancreatic cancer by administering cardenolide uscharin extracted from Calotropis procera plants | UNIBIOSCREEN S.A. (BE) | 2011-07-19 | — | — | US | disclosed |
| EP-2336134-A1 | Fitness assay and methods for reducing resistance of HIV to therapy | The United States of America, represented by the Secretary, Department of Health and Human Services (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-1088098-B1 | MEDICAMENT FOR TREATING HIV-INFECTED MAMMALS | US OF AMERICA REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES (US) | 2011-03-09 | — | — | EP | disclosed |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | GILEAD SCIENCES, INC. | 2009-12-17 | — | — | US | disclosed |
| EP-1458447-A2 | COMBINATION OF CYTOCHOME P 450 DEPENDENT PROTEASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004076434-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076433-A1 | DIPEPTIDYL PEPTIDASE INHIBITORS | AIC (BE) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004055039-A1 | STEROID COMPOUNDS WITH ANTI-TUMOR ACTIVITY | UNIBIOSCREEN S.A. (BE) | 2004-07-01 | — | — | WO | disclosed |
| WO-2004033465-A1 | 2' OXO-VORUSCHARIN AND DERIVATIVES THEREOF | UNIBIOSCREEN S.A. (BE) | 2004-04-22 | — | — | WO | disclosed |
| EP-1408043-A1 | 2''oxo-voruscharin and analogues thereof | Unibioscreen S.A. (BE) | 2004-04-14 | — | — | EP | disclosed |
| WO-2003049746-A2 | COMBINATION OF CYTOCHOME P450 DEPENDENT PROTEASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-06-19 | — | — | WO | disclosed |
| EP-1088098-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND SOCIAL SERVICES (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999067254-A2 | MULTI-DRUG RESISTANT RETROVIRAL PROTEASE INHIBITORS AND USE THEREOF | THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
| WO-1999067417-A2 | FITNESS ASSAY AND ASSOCIATED METHODS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140011815-A1 | FITNESS ASSAY AND ASSOCIATED METHODS | CPS1, CTSS, TST | ALDH1A1 1735/4885LMNA 3840/4885MAPK1 4242/4885 |
| US-20090312318-A1 | THERAPEUTIC COMPOUNDS AND METHODS | SERPINB1, ABCC1, SERPINB6 | ALDH1A1 1840/4885LMNA 741/4885MAPK1 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.